Acknowledgement
이 논문은 2020학년도 충북대학교 학술연구지원사업의 연구비 지원에 의해 연구되었음.
References
- Gwon HS. Treatment Guideline for Diabetes, 6th edition. Journal of Korean Diabetes, 2019:57-58.
- Cornell S. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. J Clin Pharm Ther 2012;37(5):510-24. https://doi.org/10.1111/j.1365-2710.2012.01342.x
- Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systemiatic review and meta-analysis. JAMA 2007;298:194-206. https://doi.org/10.1001/jama.298.2.194
- Mendonca F, Martin-Gutierrez F, Rios-Martin J, Camacho-Martinez F. Three cases of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors - one due to linagliptin. Dermatology 2016;232:249-53. https://doi.org/10.1159/000443330
- Yi H, Lee JH, Shin JY. Signal Detection for Cardiovascular Adverse Events of DPP-IV Inhibitors Using the Korea Adverse Event Reporting System Database, 2008-2016. Yonsei Med J 2019;60(2):200-7. https://doi.org/10.3349/ymj.2019.60.2.200
- Pinto LC, Rados D, Barkan S, Leitao C, Gross J. Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: a meta-analysis with trial sequential analysis. Sci Rep 2018;8(1):782.
- Kim NH. Comparison of DPP-IV inhibitors. J Korean Diabetes 2013;14:111-9. https://doi.org/10.4093/jkd.2013.14.3.111
- Seo J, Lee J, Chae G, Lee S, Jung R, Shin W. Application of electronic data standard for drug safety reporting in Korea. J Health Info Stat 2017;42(3):199-207. https://doi.org/10.21032/jhis.2017.42.3.199
- Choi NK, Park BJ. Adverse drug reaction surveillance system in Korea. J Prev Med Public Health 2007;40(4):278-84. https://doi.org/10.3961/jpmph.2007.40.4.278
- Kim S, Wang B, Lee J, et al. Statistical analysis system of spontaneous adverse drug reaction reports. J Korean Soc Clin Pharmacol Ther 2012;20(2):155-64. https://doi.org/10.12793/jkscpt.2012.20.2.155
- Sato K, Mano T, Iwata A, Toda T. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese adverse drug event report database. J Neurooncol 2019;145:1-9. https://doi.org/10.1007/s11060-019-03273-1
- Kathleen R. Richard. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther 2011;33;1609-29. https://doi.org/10.1016/j.clinthera.2011.09.028
- Huang J, Jia Y, Sun S, Meng L. Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system. BMC Pharmacol Toxicol 2020;21(1):68.
- Wilemen MJ, Mantel-Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC, Leufkens HG. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization vigibase. Diabetes Care 2011;34:369-74. https://doi.org/10.2337/dc10-1771
- Varpuluoma O, Forsti AK, Jokelainen J, et al. Vildagliptin significantly increases the risk of bullous pemphigoid: a finnish nationwide registry study. J Invest Dermatol 2018;138(7):1659-61. https://doi.org/10.1016/j.jid.2018.01.027
- Kridin K, Bergman R. Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients. JAMA Dermatol 2018;154(10):1152-58. https://doi.org/10.1001/jamadermatol.2018.2352
- Lee SG, Lee HJ, Yoon MS, Kim DH. Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes. JAMA Dermatol 2019;155(2):172-7. https://doi.org/10.1001/jamadermatol.2018.4556
- Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Front Immunol 2019;4(10):1238.
- Gonzalez-Gronow M, Kaczowka S, Gawdi G, PizzoSV. Dipeptidyl peptidase IV (DPP IV/CD26) is a cell-surface plasminogen receptor. Front Biosci 2008;13:1610-18. https://doi.org/10.2741/2785
- Hofmann SC, Voith U, Schonau V, Bruckner-Tuderman L, Franzke C. Plasmin plays a role in the in vitro generation of the linear IgA dermatosis antigen LADB97. J Invest Dermatol 2009;129:1730-9. https://doi.org/10.1038/jid.2008.424
- Men P, et al. Dipeptidyl Peptidase-4 Inhibitors and Risk of Arthralgia: A Systematic Review and Meta-analysis. Diabetes Metab 2017:493-500.